New York State Common Retirement Fund
BBIO icon

New York State Common Retirement Fund’s BridgeBio Pharma BBIO Stock Holding History

New York State Common Retirement Fund’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
222,417
+60,416
+37% +$4.23M 0.02% 551
2026
Q1 		$12M Buy
162,001
+67,817
+72% +$4.92M 0.02% 635
2025
Q4 		$7.2M Sell
94,184
-7,976
-8% -$524K 0.01% 884
2025
Q3 		$5.31M Buy
102,160
+10,806
+12% +$527K 0.01% 1039
2025
Q2 		$3.94M Buy
91,354
+6,000
+7% +$218K 0.01% 1162
2025
Q1 		$2.95M Buy
85,354
+33,178
+64% +$1.12M ﹤0.01% 1247
2024
Q4 		$1.43M Buy
52,176
+928
+2% +$24K ﹤0.01% 1530
2024
Q3 		$1.3M Sell
51,248
-7,168
-12% -$188K ﹤0.01% 1562
2024
Q2 		$1.48M Sell
58,416
-15,744
-21% -$430K ﹤0.01% 1585
2024
Q1 		$2.29M Buy
74,160
+5,863
+9% +$199K ﹤0.01% 1420
2023
Q4 		$2.76M Buy
68,297
+20,251
+42% +$608K ﹤0.01% 1334
2023
Q3 		$1.27M Buy
48,046
+4,197
+10% +$119K ﹤0.01% 1632
2023
Q2 		$754K Sell
43,849
-11,763
-21% -$177K ﹤0.01% 1906
2023
Q1 		$922K Sell
55,612
-16,674
-23% -$194K ﹤0.01% 1893
2022
Q4 		$551K Sell
72,286
-26
-0% -$249 ﹤0.01% 2270
2022
Q3 		$719K Buy
72,312
+97
+0.1% +$1.01K ﹤0.01% 2151
2022
Q2 		$656K Sell
72,215
-84
-0.1% -$703 ﹤0.01% 2225
2022
Q1 		$734K Sell
72,299
-109,348
-60% -$1.12M ﹤0.01% 2245
2021
Q4 		$3.03M Buy
181,647
+18,295
+11% +$774K ﹤0.01% 1552
2021
Q3 		$7.66M Sell
163,352
-132,727
-45% -$7.11M 0.01% 1126
2021
Q2 		$18M Buy
296,079
+15,834
+6% +$904K 0.02% 723
2021
Q1 		$17.3M Buy
280,245
+78,556
+39% +$5.14M 0.02% 706
2020
Q4 		$14.3M Buy
201,689
+122,433
+154% +$5.91M 0.02% 781
2020
Q3 		$2.97M Hold
79,256
– – ﹤0.01% 1371
2020
Q2 		$2.58M Buy
79,256
+22,456
+40% +$684K ﹤0.01% 1430
2020
Q1 		$1.65M Buy
56,800
+36,800
+184% +$1.14M ﹤0.01% 1498
2019
Q4 		$701K Buy
20,000
+2,300
+13% +$63.8K ﹤0.01% 2118
2019
Q3 		$380K Buy
+17,700
New +$490K ﹤0.01% 2467

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

New York State Common Retirement Fund's BBIO Position: Q2 2026 in Review

New York State Common Retirement Fund increased its BridgeBio Pharma (BBIO) stake by 37% in Q2 2026, buying an estimated $4.23M and bringing the position to 222,417 shares worth $16.6M. The position accounts for 0.02% of the portfolio, ranked #551.

New York State Common Retirement Fund first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $18M in Q2 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • New York State Common Retirement Fund held 222,417 shares of BridgeBio Pharma worth $16.6M as of Q2 2026.
  • New York State Common Retirement Fund bought 60,416 BridgeBio Pharma shares in Q2 2026, an estimated $4.23M.
  • BridgeBio Pharma made up 0.02% of New York State Common Retirement Fund's portfolio in Q2 2026, its #551 holding.
  • New York State Common Retirement Fund first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • New York State Common Retirement Fund's BridgeBio Pharma position peaked at $18M in Q2 2021.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.